TheraPEAK® AmpliCell® Cytokines For Ex Vivo Cell Culture

By Janet J. Sei, Rahul Purohit, Samatha Bandapalle, Sree Pulugulla, Aman Mehrorta, Ivan Lorenzo-Moldero, Dammar Thapa, Bart van Dijk, Melanie Smits, Roland Meesters, Germaine Penders, Chengkang Zhang, and Tamara Laskowski

Investigating the critical components for successful CAR-T cell manufacturing is vital for advancing cell and gene therapies. This analysis reviews the performance of TheraPEAK AmpliCell Cytokines (recombinant human IL-2, IL-7, and IL-15) compared to a leading competitor in PBMC expansion and CAR-T product quality.

The study demonstrates that using TheraPEAK AmpliCell Cytokines in either serum-containing or serum-free media systems yields comparable results to the competitor in terms of high cell viability and expansion of total nucleated cells and T cells. Significantly, when cultured with TheraPEAK AmpliCell Cytokines, CD8+ T cells showed lower levels of the TIM3 exhaustion marker. Furthermore, CAR-T cells generated using these cytokines exhibited equivalent transduction efficiency and robust cytotoxic function against tumor cells. These results confirm that TheraPEAK AmpliCell Cytokines can support the manufacture of robust, healthy T cell products with strong quality attributes.

Explore the full data set to see how these cytokines perform across different media systems.